Page 52 - Read Online

Cui et al. Microbiome Res Rep. 2025;4:31 https://dx.doi.org/10.20517/mrr.2025.25 Page 13 of 14

Metab. 2021;35:101493. DOI PubMed
53. Finn PD, Rodriguez D, Kohler J, et al. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed
mice. Am J Physiol Gastrointest Liver Physiol. 2019;316:G412-24. DOI PubMed PMC
54. Lun W, Yan Q, Guo X, et al. Mechanism of action of the bile acid receptor TGR5 in obesity. Acta Pharm Sin B. 2024;14:468-91. DOI
PubMed PMC
55. Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid
loading. Cell Metab. 2011;14:747-57. DOI PubMed PMC
56. Boutagy NE, McMillan RP, Frisard MI, Hulver MW. Metabolic endotoxemia with obesity: is it real and is it relevant? Biochimie.
2016;124:11-20. DOI PubMed PMC
57. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-72. DOI
PubMed
58. Mohammad S, Thiemermann C. Role of metabolic endotoxemia in systemic inflammation and potential interventions. Front Immunol.
2020;11:594150. DOI PubMed PMC
59. Ye D, Lammers B, Zhao Y, Meurs I, Van Berkel TJ, Van Eck M. ATP-binding cassette transporters A1 and G1, HDL metabolism,
cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis. Curr Drug Targets. 2011;12:647-60. DOI
PubMed
60. Gojda J, Cahova M. Gut microbiota as the link between elevated BCAA serum levels and insulin resistance. Biomolecules.
2021;11:1414. DOI PubMed PMC
61. Vanweert F, Schrauwen P, Phielix E. Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2
diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes. Nutr Diabetes. 2022;12:35. DOI PubMed PMC
62. Daniel N, Nachbar RT, Tran TTT, et al. Gut microbiota and fermentation-derived branched chain hydroxy acids mediate health
benefits of yogurt consumption in obese mice. Nat Commun. 2022;13:1343. DOI PubMed PMC
+
63. Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai Y. Identification and functional characterization of a Na -
independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem. 1999;274:19745-51. DOI PubMed
64. Wallace M, Green CR, Roberts LS, et al. Enzyme promiscuity drives branched-chain fatty acid synthesis in adipose tissues. Nat Chem
Biol. 2018;14:1021-31. DOI PubMed PMC
65. Green CR, Wallace M, Divakaruni AS, et al. Branched-chain amino acid catabolism fuels adipocyte differentiation and lipogenesis.
Nat Chem Biol. 2016;12:15-21. DOI PubMed PMC
66. Zaganjor E, Yoon H, Spinelli JB, et al. SIRT4 is an early regulator of branched-chain amino acid catabolism that promotes
adipogenesis. Cell Rep. 2021;36:109345. DOI PubMed PMC
67. Yoneshiro T, Wang Q, Tajima K, et al. BCAA catabolism in brown fat controls energy homeostasis through SLC25A44. Nature.
2019;572:614-9. DOI PubMed PMC
68. Ejtahed HS, Angoorani P, Soroush AR, Hasani-Ranjbar S, Siadat SD, Larijani B. Gut microbiota-derived metabolites in obesity: a
systematic review. Biosci Microbiota Food Health. 2020;39:65-76. DOI PubMed PMC
69. Mansoori S, Ho MY, Ng KK, Cheng KK. Branched-chain amino acid metabolism: pathophysiological mechanism and therapeutic
intervention in metabolic diseases. Obes Rev. 2025;26:e13856. DOI PubMed PMC
70. Van Hul M, Cani PD. The gut microbiota in obesity and weight management: microbes as friends or foe? Nat Rev Endocrinol.
2023;19:258-71. DOI PubMed
71. Nemoto S, Kubota T, Ohno H. Exploring body weight-influencing gut microbiota by elucidating the association with diet and host
gene expression. Sci Rep. 2023;13:5593. DOI PubMed PMC
72. Velloso LA, Folli F, Saad MJ. TLR4 at the crossroads of nutrients, gut microbiota, and metabolic inflammation. Endocr Rev.
2015;36:245-71. DOI PubMed
73. Sanmiguel C, Gupta A, Mayer EA. Gut microbiome and obesity: a plausible explanation for obesity. Curr Obes Rep. 2015;4:250-61.
DOI PubMed PMC
74. Ecklu-Mensah G, Choo-Kang C, Maseng MG, et al. Gut microbiota and fecal short chain fatty acids differ with adiposity and country
of origin: the METS-microbiome study. Nat Commun. 2023;14:5160. DOI PubMed PMC
75. Visuthranukul C, Sriswasdi S, Tepaamorndech S, et al. Enhancing gut microbiota and microbial function with inulin supplementation
in children with obesity. Int J Obes. 2024;48:1696-704. DOI PubMed PMC
76. Slouha E, Rezazadah A, Farahbod K, Gerts A, Clunes LA, Kollias TF. Type-2 diabetes mellitus and the gut microbiota: systematic
review. Cureus. 2023;15:e49740. DOI PubMed PMC
77. Zeng Y, Wu Y, Zhang Q, Xiao X. Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases. mBio.
2024;15:e0203223. DOI PubMed PMC
78. Wu J, Yang K, Fan H, Wei M, Xiong Q. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus. Front
Endocrinol. 2023;14:1114424. DOI PubMed PMC
79. Hernández-Montoliu L, Rodríguez-Peña MM, Puig R, et al. A specific gut microbiota signature is associated with an enhanced GLP-1
and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass. Front
Endocrinol. 2023;14:1181744. DOI PubMed PMC
80. Byndloss M, Devkota S, Duca F, et al. The gut microbiota and diabetes: research, translation, and clinical applications - 2023 Diabetes,
Diabetes Care, and Diabetologia Expert Forum. Diabetes Care. 2024;47:1491-508. DOI PubMed PMC